Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation

被引：1
|
作者：
Oran, Betul
Alatrash, Gheath
Alousi, Amin M.
Mehta, Rohtesh S.
Hosing, Chitra
Popat, Uday R.
Im, Jin S.
McCarty, Jessica M.
Ramos, Jennifer D.
Keer, Harold N.
Thall, Peter F.
Champlin, Richard E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134272
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment
    Sebert, Marie
    Bally, Cecile
    Peterlin, Pierre
    Beyne-Rauzy, Odile
    Legros, Laurence
    Gourin, Marie Pierre
    Sanhes, Laurence
    Wattel, Eric
    Gyan, Emmanuel
    Park, Sophie
    Stamatoullas, Aspasia
    Banos, Anne
    Laribi, Kamel
    Jueliger, Simone
    Bevan, Luke
    Chaffaut, Cendrine
    Sapena, Rosa
    Samey, Benedicte
    Chermat, Fatiha
    Chevret, Sylvie
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2016, 128 (22)
  • [2] 5-AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK AML AND MDS
    Puglisi, Bruna
    Saraceni, Francesco
    Guerzoni, Selene
    Scortechini, Ilaria
    Mancini, Giorgia
    Fiorentini, Alessandro
    Lotito, Antonio
    Colaneri, Francesca Romana
    Federici, Irene
    Olivieri, Attilio
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 364 - 365
  • [3] Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML
    El Chaer, Firas
    Borate, Uma
    Dulery, Remy
    Holtan, Shernan G.
    Law, Arjun Datt
    Muffly, Lori
    Nassereddine, Samah
    Shallis, Rory M.
    Stringaris, Kate
    Taylor, Justin
    Devine, Steven M.
    Mohty, Mohamad
    Hourigan, Christopher S.
    BLOOD ADVANCES, 2021, 5 (06) : 1757 - 1759
  • [4] Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients
    Danylesko, Ivetta
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    BLOOD, 2019, 134
  • [5] Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients
    Danylesko, Ivetta
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S179 - S180
  • [6] The outcome of allogeneic stem cell transplantation in patients with high risk MDS and AML: single center experience
    Halahleh, Khalid
    Odaily, Sarah
    Al Tell, Abdallah
    Al-Awabdeh, Tala
    Ma'kosa, Mohammad
    Najjar, Rula
    Rihani, Rawad
    Abu Shanab, Mayada
    Hussein, Nilly
    Khattab, Eman
    Sharma, Shanta
    Abu Khader, Ahmad
    Yousef, Dana
    Abu-Jazar, Husam
    Tbakhi, Abdelghani
    Sarhan, Mahmoud
    BONE MARROW TRANSPLANTATION, 2018, 53 : 189 - 190
  • [7] Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)
    Morita, Kiyomi
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Bodden, Kristy R.
    Wang, Feng
    Bose, Prithviraj
    Alvarado, Yesid
    Daver, Naval
    Borthakur, Gautam
    Ravandi, Farhad
    Takahashi, Koichi
    Jabbour, Elias
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Ohanian, Maro
    Pierce, Sherry A.
    Azab, Mohammad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [8] Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Montalban-Bravo, Guillermo
    Bodden, Kristy R.
    Bose, Prithviraj
    Alvarado, Yesid
    Daver, Naval G.
    Borthakur, Gautam
    Ravandi, Farhad
    Takahashi, Koichi
    Cortes, Jorge E.
    Jabbour, Elias J.
    Naqvi, Kiran
    DiNardo, Courtney D.
    Benton, Christopher B.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Ohanian, Maro N.
    Pierce, Sherry A.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [9] Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation
    Heuser, Michael
    Koenecke, Christian
    Gabdoulline, Razif
    Loeffeld, Patrick
    Dobbernack, Vera
    Panagiota, Victoria
    Klesse, Sabrina
    Stadler, Michael
    Krauter, Juergen
    Dammann, Elke
    Wichmann, Martin
    Shahswar, Rabia
    Bhuju, Sabin
    Geffers, Robert
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Kleine, Moritz
    Brauns, Wiebke
    Platzbecker, Uwe
    Thiede, Christian
    Schroeder, Thomas
    Kobbe, Guido
    Ganser, Arnold
    Kroeger, Nicolaus
    Thol, Felicitas
    BLOOD, 2015, 126 (23)
  • [10] AZACYTIDINE MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IMPROVES OUTCOME IN HIGH RISK MDS AND AML PATIENTS: A PROPENSITY SCORE ANALYSIS FROM THE SFGM-TC
    Gournay, Viviane
    Alcazer, Vincent
    Desmier, Deborah
    Dulery, Remy
    Quoc, Stephanie Nguyen
    Francois, Sylvie
    Chalandon, Yves
    Rubio, Marie-Therese
    Damaj, Gandhi Laurent
    Huynh, Anne
    Forcade, Edouard
    Mear, Jean-Baptiste
    Turlure, Pascal
    Tavernier, Emmanuelle
    Villate, Alban
    Berceanu, Ana
    Lioure, Bruno
    Maury, Sebastien
    Robin, Marie
    Marcais, Ambroise
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 334 - 335
12345